BIO-TECHNE ANNOUNCES EXCLUSIVE DEVELOPMENT AND LICENSE AGREEMENT WITH THERMO FISHER SCIENTIFIC FOR ExoTRU® KIDNEY TRANSPLANT REJECTION ASSAY

Bio-Techne Corporation (NASDAQ: TECH) has partnered with Thermo Fisher Scientific to develop and commercialize the ExoTRU kidney transplant rejection test.

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) has partnered with Thermo Fisher Scientific to develop and commercialize the ExoTRU kidney transplant rejection test. This non-invasive liquid biopsy assay provides critical allograft health information, aiding in the management of kidney transplant patients by distinguishing between T-cell mediated rejection and antibody mediated rejection. Developed with the Azzi Laboratory at Harvard Medical School's Transplantation Research Center, the ExoTRU assay meets a significant need in patient care and has potential for market leadership in liquid biopsies.

Positive

• Partnership with Thermo Fisher Scientific enhances the commercialization of ExoTRU.
• ExoTRU fills a significant unmet need in kidney transplant patient management.
• The assay differentiates between two types of kidney transplant rejections, potentially improving patient outcomes.

Negative

• None.

Argus Session date unavailable

-0.22% session move Open Argus

Details

News Market Reaction – TECH

The recorded move for TECH in the trading session of this news was -0.22%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, Feb. 22, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize the ExoTRU kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand.

ExoTRU is a non-invasive multigene urine based liquid biopsy assay that provides critical allograft health information to assist clinician decision making in managing kidney transplant patients and optimizing patient care. The assay has the potential to discriminate between T-cell mediated rejection (TCMR) and antibody mediated rejection (ABMR), which is critical to improving patient management and outcomes.  ExoTRU was developed in collaboration with the Azzi Laboratory at the Transplantation Research Center at Brigham and Women's Hospital, Harvard Medical School.

"We continue to demonstrate the utility of exosomes as a source of significant clinical value for non-invasive testing. ExoTRU is another great example of this potential, with this assay filling a significant unmet need in the area of kidney transplant patient care," commented Kim Kelderman, President of Bio-Techne's Diagnostics and Genomics Segment. "Thermo Fisher is the ideal partner to complete development of and commercialize ExoTRU, with its trusted reputation and established transplant center relationships creating the ideal channel to drive awareness and adoption of this best-in-class assay."

"We see tremendous potential for ExoTRU to improve the care offered to kidney transplant patients and scale into a market leading liquid biopsy test," said John Sos, Senior Vice President and President, Specialty Diagnostics at Thermo Fisher Scientific. "We look forward to partnering with Bio-Techne to bring this important innovation to market."

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-exclusive-development-and-license-agreement-with-thermo-fisher-scientific-for-exotru-kidney-transplant-rejection-assay-301485617.html

SOURCE Bio-Techne Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the ExoTRU kidney transplant rejection test by Bio-Techne?

The ExoTRU test is a non-invasive multigene urine-based liquid biopsy assay that helps manage kidney transplant patients by providing critical allograft health information.

Who are Bio-Techne's partners in the ExoTRU test development?

Bio-Techne has partnered with Thermo Fisher Scientific to exclusively develop and commercialize the ExoTRU kidney transplant rejection test.

What is the significance of the ExoTRU assay in kidney transplant management?

The ExoTRU assay is significant as it can distinguish between T-cell mediated rejection and antibody mediated rejection, which is crucial for improving patient management and outcomes.

When was the partnership for ExoTRU officially announced?

The partnership was announced on February 22, 2022.

What is the ticker symbol for Bio-Techne Corporation?

The ticker symbol for Bio-Techne Corporation is TECH.